9 Meters Biopharma, Inc. announced plans to conduct a Phase 3 trial with vurolenatide in patients with short bowel syndrome (SBS). However, following further consideration of feedback received previously from the U.S. Food and Drug Administration (FDA) and input from thought leaders and investors, the Company now believes an additional Phase 2 trial may maximize the potential for vurolenatide. In addition, as the Company continues to assess various strategic alternatives, if and when funding is available, the Company will update on the initiation of the timing of this Phase 2 trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
2023 | Bidding Procedure Approved for 9 Meters Biopharma, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 14 | |
+158.06% | 6.17B | |
+0.47% | 998M | |
+2.10% | 982M | |
+41.91% | 872M | |
+22.89% | 803M | |
+1.63% | 663M | |
-1.26% | 596M | |
-.--% | 600M | |
+32.01% | 601M |
- Stock Market
- Equities
- NMTRQ Stock
- News 9 Meters Biopharma, Inc.
- 9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome